Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer: A Practical Guide for Oncologists, Advanced Practice Providers, and Pharmacists.

The multikinase inhibitor regorafenib has improved outcomes for patients with metastatic colorectal cancer (mCRC) following failure of standard therapies. However, regorafenib may be associated with treatment-emergent adverse events (TEAEs) requiring dose modifications. The regorafenib dose-optimization study (ReDOS) investigated a systematic method for titrating regorafenib up to the highest tolerable dose through a prospective evaluation of a first-cycle dose-escalation strategy, compared with standard dosing in patients with refractory mCRC. ReDOS met its primary endpoint, with more patients starting cycle 3 in the dose-escalation group (43%) vs. the standard-dose group (26%; p = .043). The safety profile was consistent with previous reports, and the incidence of regorafenib-related grade 3 TEAEs was generally lower in the dose-escalation group vs. the standard-dose group in cycles 1 and 2. Secondary endpoints showed that dose escalation did not negatively impact efficacy. Initiating regorafenib below the approved standard dose (160 mg/day) improves tolerability and allows health-care professionals to individualize the dose during cycles 1 and 2 without reducing overall drug exposure. This strategy provides an evidence-based guide to optimize regorafenib dosing and improve tolerability without compromising efficacy, allowing patients to remain on regorafenib for longer and potentially improve outcomes. This review provides a clinically relevant appraisal of ReDOS and the implications for patient management from the perspective of oncologists, advanced practice providers, and pharmacists.

• Publication year

  2025

• Venue

  Journal of the Advanced Practitioner in Oncology

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/jadpro.2025.16.7.31PMID 41346776PMCID PMC12673991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

  2022cited by this paper
• Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.

  2021cited by this paper
• Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

  2021cited by this paper
• Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.

  2021cited by this paper
• The Expanding Role of the Oncology Pharmacist

  2020cited by this paper
• Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

  2020cited by this paper
• Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.

  2019cited by this paper
• Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

  2019cited by this paper
• Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

  2019cited by this paper
• Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

  2019cited by this paper
• Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.

  2019cited by this paper
• Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

  2018cited by this paper
• Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

  2018cited by this paper
• Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer

  2017cited by this paper
• Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

  2017cited by this paper
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• The role of Advanced Practice Providers in interdisciplinary oncology care in the United States.

  2016cited by this paper
• Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

  2016cited by this paper
• Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

  2015cited by this paper
• Regorafenib: start low and go slow

  2015cited by this paper
• Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events

  2015cited by this paper
• Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

  2015cited by this paper
• Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer

  2015cited by this paper
• Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

  2014cited by this paper
• Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

  2013cited by this paper
• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Prevention and management of adverse events related to regorafenib

  2013cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

  2011cited by this paper
• Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

  2011cited by this paper
• Filling the gap: development of the oncology nurse practitioner workforce.

  2010cited by this paper
• Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

  2008cited by this paper
• Cancer-related fatigue: the scale of the problem.

  2007cited by this paper
• Systemic therapy for metastatic colorectal cancer: current options, current evidence.

  2005cited by this paper
• The rapid assessment of fatigue severity in cancer patients

  1999cited by this paper
• Quality of life in hospice patients. A pilot study.

  1999cited by this paper

• No citing papers are available for this paper.